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Objectives: 
Diabetes mellitus (DM) is a known metabolic disorder characteristic of developed countries and with high prevalence in children and adolescent. Recently, World 
Health Organization had indicated that DM is the world’s fastest-growing disease, being responsible for almost 3 million deaths worldwide per year1. Type 1 and 
type 2 DM are both associated with a continuous hyperglycemic condition that contributes to the development of other dangerous pathologies such as obesity, 
hypertension and cardiovascular diseases2. At the moment, some anti-diabetic treatments are available, since synthetic drugs to insulin injections; but the painful, 
discomfort and the lack of efficiency of these strategies ask for a drug that solves this current problem3. In recent years, different studies have emerged about the 
anti-diabetic properties of vanadium compounds. The potentiality of these agents encouraged their use in human clinical trials; however the toxicological effects 
compromise their success4. Recently, a more efficient insulin-mimetic drug, Bis-[3-hydroxy-1,2-dimethyl-4-pyridinonato] oxovanadium (IV), also called 
VO(dmpp)2, has been studied5. The efficacy obtained with this compound in vitro encouraged further work, paving the way to implement this insulin-mimetic 
compound in clinical trials. Therefore, an in vivo study was conducted using obese Zucker rats as an animal model of obesity and insulin resistance. The aim of this 
study is to elucidate the effect of VO(dmpp)2 on impaired lipid and glucose metabolism of pre-diabetic obese Zucker rats6 by using in vivo Magnetic Resonance 
and others biological techniques.  
 
Methods:  
Lean Zucker (fa/+) and obese Zucker (fa/fa) rats (7 weeks-old) were used to unveil the insulin-mimetic properties of VO(dmpp)2 in vivo. During four weeks, the 
animals were daily weighted and intraperitoneally injected with VO(dmpp)2 compound (15 mg/Kg body weight) or serum, being divided in four groups: 
VO(dmpp)2-treated lean rats (n=6), lean non-treated rats (n=8), VO(dmpp)2-treated obese rats (n=7) and obese non-treated rats (n=7). Once a week, the animals 
were assessed in terms of hepatic triglyceride (HTG) content determined by 1H MRS and studied by in vivo MRI. On the last day of the experiment, a glucose 
tolerance test was performed and blood was withdrawn from the tail of overnight fasted animals to determine possible toxicological effects.  
 
Results: 
After the VO(dmpp)2 treatment, different parameters indicative of obesity, insulin resistance and pre-diabetes were reverted in obese Zucker rats such as, gain of 
body weight (Figure 1), subcutaneous fat width (Figure 2), glucose intolerance profile and high HTG content (Figure 3). The lack of renal toxicity in obese Zucker 
rats treated with VO(dmpp)2 showed the efficiency of this potential drug to revert obesity symptoms in non-toxic concentrations.  
 
Figure 1 – Gain of body weight of Zucker rats submitted to different treatments during four weeks: the lean-treated rats (dark blue), the lean non-treated rats 
(pink), the obese vanadium-treated rats (yellow) and the obese non-treated rats (light blue). The trendline was drawn to each group of animals and the respective 
equations are shown. Data are present as mean values. Initially, vanadium-treated and non-treated obese Zucker rats had the same weight values; however after 
VO(dmpp)2 treatment vanadium-treated obese Zucker rats had a gain of body weight lower than non-treated obese Zucker rats.  
 
 
Figure 2 - Coronal T1-weighted images of the liver of four different Zucker rats. T1-weighted 
images of the liver of a non-treated lean rat (column A), VO(dmpp)2-treated lean rat (column B), 
VO(dmpp)2-treated obese rat (column C) and non-treated obese rat (column D), in the first day 
(top) and in the last day of the study (bottom). The difference between the subcutaneous fat width 
of obese-treated and obese non-treated rat is shown by the arrows. During the treatment with 
VO(dmpp)2, the thickness of subcutaneous fat is minimized in obese-treated animals, in contrast 
with obese non-treated rats. Indeed, this remarkable difference is a consequence of VO(dmpp)2 
treatment, qualitatively proving the action of this compound on the impaired lipid metabolism of 
obese Zucker rats.  
 
 
Figure 3 - Quantification of HTG in lean and obese Zucker rats during the four weeks of 
VO(dmpp)2 treatment. The quantification of the HTG content was done by the ratio between the 
peak areas of 1H fat signal and 1H water signal, obtained by 1H MRS technique. Obese Zucker rats 
presented high levels of HTG since the first day of the study. However, after the first week of 
VO(dmpp)2 treatment, the HTG content remarkably decreased in the obese-treated animals, 
whereas HTG in non-treated obese rats remained high. In the last day of the treatment, the 
significantly difference between Fat/H2O ratio of obese-treated and obese non-treated Zucker rats 
demonstrated the action of VO(dmpp)2 on revert the high HTG profile of obese Zucker rats. Data 
are shown as mean values ± SEM. Paired bilateral t test was used in statistical analysis where 
P<0.05 was considered to be significant. * P<0.0005 relative to the respective day of obese non-
treated Zucker animals. Δ P<0.005 relative to the day 0 of obese-treated Zucker rats. # P<0.05 
relative to the day 0 of obese-treated Zucker rats. 
 
Conclusion: 
In summary, this study proved that VO(dmpp)2 compound acts on glucose and lipid metabolism of the obese Zucker rat, reverting its pre-diabetic profile3 within a 
non-toxic range. Consequently, VO(dmpp)2 becomes a strong candidate to enter in future clinical trials to be used against steatosis, obesity or Type 2 DM. 
 
References: 1) Wild S et al. Diabetes Care. 2004, 27(5):1047-1053. 2) Hsueh W et al. Postgrad Med. 2010, 122(4):129-43. 3) Sakurai H et al. Chemical Society 
Reviews, 2008, 37(11):2383-2392. 4) Thompson K et al. Journal of Inorganic Biochemistry. 2009, 103(4):554-558. 5) Passadouro M et al. Journal of Inorganic 
Biochemistry. 2010, 104(9):987-992. 6) Augstein P & Salzsieder E. Methods in Molecular Biolog. 2009, 560:159-189.  
Proc. Intl. Soc. Mag. Reson. Med. 19 (2011) 1538
